Morphine versus methadone for neonatal opioid withdrawal syndrome: a randomized controlled pilot study

Mary Beth Sutter, Hannah Watson, Nicole Yonke, Sherry Weitzen, Lawrence Leeman, Mary Beth Sutter, Hannah Watson, Nicole Yonke, Sherry Weitzen, Lawrence Leeman

Abstract

Background: Neonatal Opioid Withdrawal Syndrome (NOWS) is a significant public health issue and while millions of neonates are affected each year, an optimal pharmacologic weaning protocol has yet to be demonstrated. In this study, we compare hospital length of stay (LOS) and length of treatment (LOT) for treatment of neonatal opioid withdrawal (NOWS) with morphine versus methadone.

Methods: This was a single-site, open-label, randomized controlled pilot study conducted from October 2016-September 2018. Infants were eligible if their primary in-utero drug exposure was heroin, oral opioids, or methadone and they were born at greater than or equal to 34 weeks gestation. Infants were excluded for serious medical comorbidities and primary in-utero exposure to buprenorphine.

Results: Sixty-one infants were enrolled; 30 were randomized to methadone treatment, and 31 to morphine treatment. Overall 46% of infants required treatment for NOWS. LOS and LOT for infants treated with morphine was 17.9 days and 14.7 days respectively, compared to 16.1 days and 12.8 days for babies treated with methadone (p = 0.5, p = 0.54). Infants treated with morphine received lower total morphine equivalents than those treated with methadone (9.7 vs. 33, p < 0.01). Three treated infants in the methadone group required transfer to the Neonatal Intensive Care Unit, versus no infants in the morphine group.

Conclusions: Infants treated with morphine versus methadone had no significant differences in LOS or LOT in this pilot study. Infants treated with methadone received up to 3 times the opioid based on morphine equivalents as infants treated with morphine and had more transfers to the NICU for over sedation.

Clinical trial registration: Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome NCT02851303 , initiated 01/08/2016.

Keywords: Methadone; Neonatal opioid withdrawal syndrome; Perinatal substance use disorders.

Conflict of interest statement

There were no competing interests of any of the authors of this study.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Screen, exclusion, consent rate, randomization, and treatment completion by study group (10/1/16- 9/30/18). NICU = Neonatal intensive care unit.The total rate of neonatal opioid withdrawal requiring pharmacologic treatment was n = 28 or 46%

References

    1. Hudak ML, Tan RC. THE COMMITTEE ON DRUGS, & THE COMMITTEE ON FETUS AND NEWBORN. Neonatal Drug Withdrawal Pediatrics. 2012;129:e540–e560.
    1. Devlin L, Davis J. A Practical Approach to Neonatal Opiate Withdrawal Syndrome. Am J Perinatol. 2018;35:324–330. doi: 10.1055/s-0037-1608630.
    1. Jansson LM, Patrick SW. Neonatal Abstinence Syndrome. Pediatr Clin North Am. 2019;66:353–367. doi: 10.1016/j.pcl.2018.12.006.
    1. Clemans-Cope L, et al. Pregnant women with opioid use disorder and their infants in three state Medicaid programs in 2013–2016. Drug Alcohol Depend. 2019;195:156–163. doi: 10.1016/j.drugalcdep.2018.12.005.
    1. Leech AA, Cooper WO, McNeer E, Scott TA, Patrick SW. Neonatal Abstinence Syndrome In The United States, 2004–16: An examination of neonatal abstinence syndrome trends and incidence patterns across US census regions in the period 2004–16. Health Aff (Millwood) 2020;39:764–767. doi: 10.1377/hlthaff.2019.00814.
    1. Shrestha S, Roberts MH, Maxwell JR, Leeman LM, Bakhireva LN. Post-discharge healthcare utilization in infants with neonatal opioid withdrawal syndrome. Neurotoxicol. Teratol. 2021;86:106975. doi: 10.1016/j.ntt.2021.106975.
    1. Patrick S, Davis MM, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol. 2015;35:650–655. doi: 10.1038/jp.2015.36.
    1. Holmes AV, et al. Rooming-In to Treat Neonatal Abstinence Syndrome: Improved Family-Centered Care at Lower Cost. Pediatrics. 2016;137:e20152929–e20152929. doi: 10.1542/peds.2015-2929.
    1. Welle-Strand GK, et al. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr n/a-n/a. 2013 doi: 10.1111/apa.12378.
    1. McCarthy JJ, Leamon MH, Finnegan LP, Fassbender C. Opioid dependence and pregnancy: minimizing stress on the fetal brain. Am J Obstet Gynecol. 2017;216:226–231. doi: 10.1016/j.ajog.2016.10.003.
    1. Ebner N, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend. 2007;87:131–138. doi: 10.1016/j.drugalcdep.2006.08.024.
    1. Logan BA, Brown MS, Hayes MJ. Neonatal Abstinence Syndrome: Treatment and Pediatric Outcomes. Clin Obstet Gynecol. 2013;56:186–192. doi: 10.1097/GRF.0b013e31827feea4.
    1. Hall ES, et al. A Multicenter Cohort Study of Treatments and Hospital Outcomes in Neonatal Abstinence Syndrome. Pediatrics. 2014;134:e527–e534. doi: 10.1542/peds.2013-4036.
    1. Hall ES, et al. Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study. Pediatrics. 2015;136:e803–e810. doi: 10.1542/peds.2015-1141.
    1. Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA. Variation in treatment of neonatal abstinence syndrome in US Children’s Hospitals, 2004–2011. J Perinatol. 2014;34(11):867–72. doi: 10.1038/jp.2014.114.
    1. DeAtley HN, Burton A, Fraley MD, Haltom J. Evaluation of the Effectiveness of Two Morphine Protocols to Treat Neonatal Abstinence Syndrome in a Level II Nursery in a Community Hospital. Pharmacother J Hum Pharmacol Drug Ther. 2017;37:856–860. doi: 10.1002/phar.1966.
    1. Clemans-Cope L, et al. Neonatal abstinence syndrome management in California birth hospitals: results of a statewide survey. J Perinatol. 2020;40:463–472. doi: 10.1038/s41372-019-0568-6.
    1. Kraft WK, et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med. 2017 doi: 10.1056/NEJMoa1614835.
    1. Hall ES, et al. A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. J Pediatr. 2016;170:39–44.e1. doi: 10.1016/j.jpeds.2015.11.039.
    1. Hall E, Rice W, Folger A, Wexelblatt S. Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids. Am J Perinatol. 2018;35:405–412. doi: 10.1055/s-0037-1608634.
    1. Lainwala S, et al. A Retrospective Study of Length of Hospital Stay in Infants Treated for Neonatal Abstinence Syndrome with Methadone versus Morphine Oral Preparations. Adv in Neonat Care. 2005;5:265–272. doi: 10.1016/j.adnc.2005.06.003.
    1. Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: A prospective randomized clinical trial. J Perinatol. 2015;35:278–283. doi: 10.1038/jp.2014.194.
    1. Tolia VN, et al. Morphine vs Methadone Treatment for Infants with Neonatal Abstinence Syndrome. J Pediatr. 2018;203:185–189. doi: 10.1016/j.jpeds.2018.07.061.
    1. Davis J, et al. Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial. JAMA Peds. 2018;8:741–748. doi: 10.1001/jamapediatrics.2018.1307.
    1. Zankl A, et al. Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021;7(7):CD002059.
    1. Jones HE, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–2331. doi: 10.1056/NEJMoa1005359.
    1. Finnegan LP, Connaughton JFJ, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2:141–158.
    1. Centers for Disease Control. Calculating Total Daily Dose of Opioids for Safer Dosage from . Accessed 4 Jan 2022.
    1. Jones HE, et al. Cigarette Smoking in Opioid-dependent Pregnant Women: Neonatal and Maternal Outcomes. Drug Alcohol Depend. 2013;131:271–277. doi: 10.1016/j.drugalcdep.2012.11.019.
    1. Centers for Disease Control and Prevention, Pregnancy Risk Assessment Monitoring System, from . Accessed 4 Jan 2022.
    1. Grossman MR, et al. An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome. Pediatrics. 2017;139:e20163360. doi: 10.1542/peds.2016-3360.
    1. Wachman EM, et al. Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome. J Perinatol. 2018;38:1114–1122. doi: 10.1038/s41372-018-0109-8.
    1. Kelly LE, et al. A Core Outcome Set for Neonatal Opioid Withdrawal Syndrome. Pediatrics. 2020;146:e20200018. doi: 10.1542/peds.2020-0018.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner